Addressing Residual CV Risk In Diabetes: Focus On Lp(a) Metabolism
Funder
National Health and Medical Research Council
Funding Amount
$367,864.00
Summary
High postmeal lipid levels and fatty liver occurs commonly in Type 2 Diabetes and is associated with increased risk of cardiovascular disease. In addition to the standard risk factors of triglycerides and cholesterol, other factors, including a small protein called Lp(a) increase cardiovascular disease risk. Few therapies reduce Lp(a) and this study will examine the effect of niacin on reducing the concentration of this protein. A positive result may expand treatment choices for diabetics in red ....High postmeal lipid levels and fatty liver occurs commonly in Type 2 Diabetes and is associated with increased risk of cardiovascular disease. In addition to the standard risk factors of triglycerides and cholesterol, other factors, including a small protein called Lp(a) increase cardiovascular disease risk. Few therapies reduce Lp(a) and this study will examine the effect of niacin on reducing the concentration of this protein. A positive result may expand treatment choices for diabetics in reducing the risk of heart disease.Read moreRead less
PCSK9 is an inhibitor of the receptor that is responsible for removing LDL (the bad cholesterol) from the circulation. We will study the molecular mechanisms that inhibit PCSK9 at the protein level. This study is needed to understand if drugs that inhibit PCSK9 will diminish the risk of developing heart disease in patients who do not respond well to existing treatments, for example those who already had a cardiovascular event or those with familial hypercholesterolemia.
Postprandial Lipid Metabolism In Familial Hypercholersterolaemia: Mechanisms And Effects Of Omega-3 Fatty Acid Ethyl Esters
Funder
National Health and Medical Research Council
Funding Amount
$616,344.00
Summary
Familial hypercholesterolaemia (FH) is the most common genetic condition known to cause premature coronary heart diseaseis (CHD). The increasd CHD risk in FH may be in part due to accumulation of fat in blood. Fish oil supplementation may be a new target, additional to standard best therapy, for reducing CHD risk in FH. Our results will add value to the science behind and clinical therapy for lipid disorders in FH, and will establish a key role for fish oils.
Lipoprotein(a) Metabolism In Subjects At High Risk Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$690,735.00
Summary
Heart disease is a major health burden. Despite best evidence-based treatments, residual risk remains high. Lp(a), a small protein in the blood, is a powerful causal risk factor for premature heart disease, but little is known about its physiology or metabolism. This study will provide vital knowledge into Lp(a) metabolism and the mechanisms by which two unique therapies lower Lp(a) levels. These insights may expand treatment choices for people at risk of heart disease.
Enhancing The Blood-brain Barrier Efflux Of ?-amyloid: A Novel Approach For The Treatment Of Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$291,274.00
Summary
Alzheimer’s disease (AD) is the leading cause of dementia and is associated with the accumulation of a toxic protein in the brain. This project will investigate whether enhancing the removal of this toxic protein from the brain (by shuttling it into the blood) will restore the memory deficit associated with AD. The outcomes of this project have the potential to lead to novel strategies for the treatment of this debilitating disorder.